NEWEST CONTENT
-
ORIGINAL REPORTSTagliamento et al.January 31, 2023
-
Clinical Trial UpdatesHerbst et al.January 31, 2023
-
ORIGINAL REPORTSMatulonis et al.January 30, 2023
-
CORRESPONDENCECliff et al.January 30, 2023
-
ONCOLOGY GRAND ROUNDSTrapaniJanuary 30, 2023
FEATURED CONTENT
ORIGINAL REPORTS
Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial
Morton et al. | January 19, 2023
JUST ACCEPTED RAPID COMMUNICATION
Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study
Paz-Ares et al. | January 23, 2023
SPONSORED CONTENT
Sponsored by BRISTOL MYERS SQUIBB
First-Line Treatment of PD-L1–Negative Non–Small Cell Lung Cancer
MOST READ
(Last 60 days)-
LoConte et al.
-
Morton et al.
-
Mikhael et al.
-
Schneider et al.